Annexon Investor Relations Material
Latest events
R&D Day 2024
Annexon
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Annexon Inc
Access all reports
Annexon, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company focuses on targeting C1q, an initiating molecule of the classical complement pathway, which plays a critical role in various disease processes, including antibody-mediated autoimmune diseases and complement-mediated neurodegeneration. Annexon's pipeline includes several product candidates such as ANX005, which is in clinical trials for Guillain-Barré syndrome, and other trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Annexon is headquartered in Brisbane, California, and its shares are listed on the Nasdaq.
Key slides for Annexon Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Annexon Inc
R&D Day 2024
Annexon Inc
Latest articles
Burberry: From WWI Trench Coats to Global Luxury
Explore Burberry's journey from a small outfitter to a global luxury fashion icon under Daniel Lee's creative vision.
17 May 2024
Phil Knight: The Entrepreneurial Genius Behind Nike
The life, work, and legacy of Nike’s legendary founder Phil Knight and his path to the top of athletic footwear and apparel.
16 May 2024
Palantir Technologies and Its Broad Spectrum of Impact
Discover how Palantir Technologies, a leader in data analytics since 2003, shapes global events and keeps growing rapidly into various domains.
16 May 2024
Ticker symbol
Country
🇺🇸 United States